Physician profile
William Loftus
NPI 1386719045
$4,584.04
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,798 · 2020: $503 · 2021: $259 · 2022: $23.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $2,154.45 | 2019-2020 | |
| Abbvie INC. | $520.66 | 2019-2021 | |
| Amgen INC. | $316.15 | 2019-2020 | |
| Therapeuticsmd, INC. | $291.62 | 2019-2020 | |
| Pfizer INC. | $287.84 | 2019-2020 | |
| Lupin INC. | $167.81 | 2019 | |
| Allergan, INC. | $160.62 | 2019-2020 | |
| Myovant Sciences INC. | $124.99 | 2021 | |
| Roche Diagnostics Corporation | $99.22 | 2019 | |
| Amag Pharmaceuticals, INC. | $91.79 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.05 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $78.42 | 2019-2020 | |
| Coopersurgical, INC. | $56.34 | 2019 | |
| Hologic Sales and Service, LLC | $48.85 | 2019 | |
| Covidien LP | $21.14 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $17.92 | 2019 | |
| Ge Healthcare | $17.50 | 2021 | |
| Smith+Nephew, INC. | $17.13 | 2019 | |
| Boston Scientific Corporation | $15.38 | 2019 | |
| Radius Health, INC. | $14.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Loftus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.